March 25, 2008--Celgene Corporation (NASDAQ: CELG) announced that Amrubicin has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer. FDA's Orphan Drug Act was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions that are rare and affect 200,000 persons or less in the United States. Orphan drug designation provides an important economic incentive for the development of new products in the cancer field... Celgene's Press Release -
